NC
MRVI icon

NinePointTwo Capital’s Maravai LifeSciences MRVI Stock Holding History

NinePointTwo Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,563
Closed -$448K – 227
2022
Q3 		$448K Buy
+17,563
New +$441K 0.18% 30

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

NinePointTwo Capital's MRVI Position: Q4 2022 in Review

NinePointTwo Capital sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 17,563 shares — an estimated $448K sold.

NinePointTwo Capital first reported a position in MRVI in Q3 2022 and held it in 1 quarter. The position peaked at $448K in Q3 2022. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

  • NinePointTwo Capital reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 17,563 Maravai LifeSciences shares in Q4 2022, an estimated $448K.
  • NinePointTwo Capital first reported a position in Maravai LifeSciences in Q3 2022 and held it in 1 quarter.
  • NinePointTwo Capital's Maravai LifeSciences position peaked at $448K in Q3 2022.
  • 212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on NinePointTwo Capital's 13F filing for Q4 2022, filed 14 Feb 2023.